{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T03:14:05Z","timestamp":1785035645656,"version":"3.55.0"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T00:00:00Z","timestamp":1547769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XH-16-110385"],"award-info":[{"award-number":["W81XH-16-110385"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pennies in Action"},{"name":"Henle Foundation"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0210209","type":"journal-article","created":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T18:26:10Z","timestamp":1547835970000},"page":"e0210209","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":21,"title":["Th1 cytokines sensitize HER-expressing breast cancer cells to lapatinib"],"prefix":"10.1371","volume":"14","author":[{"given":"Loral E.","family":"Showalter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal","family":"Oechsle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirmala","family":"Ghimirey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chase","family":"Steele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Czerniecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary K.","family":"Koski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,1,18]]},"reference":[{"issue":"4","key":"ref1","first-page":"252","article-title":"Cancer treatment and survivorship statistics, 2014","volume":"64","author":"CECE DeSantis","year":"2014","journal-title":"CA: a cancer journal for clinicians"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jnci\/djq495","article-title":"Projections of the cost of cancer care in the United States: 2010\u20132020","volume":"103","author":"ABAB Mariotto","year":"2011","journal-title":"JNCI: Journal of the National Cancer Institute"},{"issue":"4","key":"ref3","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1158\/0008-5472.CAN-06-4038","article-title":"Targeting HER-2\/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion","volume":"67","author":"BJBJ Czerniecki","year":"2007","journal-title":"Cancer research"},{"issue":"17","key":"ref4","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1002\/cncr.26734","article-title":"HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ","volume":"118","author":"AA Sharma","year":"2012","journal-title":"Cancer"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/CJI.0b013e318235f512","article-title":"A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2\/neu responses in women with early breast cancer","volume":"35","author":"GKGK Koski","year":"2012","journal-title":"Journal of immunotherapy"},{"key":"ref6","article-title":"T-helper 1-type cytokines induce apoptosis and loss of HER-family oncodriver expression in murine and human breast cancer cells","author":"PP Namjoshi","year":"2016","journal-title":"Oncotarget"},{"issue":"12","key":"ref7","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1158\/1078-0432.CCR-16-1924","article-title":"Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2(pos) DCIS Independent of Route: Results of Randomized Selection Design Trial","volume":"23","author":"LL Lowenfeld","year":"2017","journal-title":"Clinical cancer research"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1158\/0008-5472.CAN-05-1182","article-title":"Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells","volume":"66","author":"GEGE Konecny","year":"2006","journal-title":"Cancer research"},{"issue":"19","key":"ref9","first-page":"7196","article-title":"The characterization of novel, dual ErbB-2\/EGFR, tyrosine kinase inhibitors: potential therapy for cancer","volume":"61","author":"DWD Rusnak","year":"2001","journal-title":"Cancer research"},{"issue":"26","key":"ref10","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"CECE Geyer","year":"2006","journal-title":"The New England journal of medicine"},{"issue":"16","key":"ref11","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1200\/JCO.2011.40.5241","article-title":"Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer","volume":"31","author":"ZZ Guan","year":"2013","journal-title":"Journal of clinical oncology"},{"issue":"9816","key":"ref12","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(11)61847-3","article-title":"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial","volume":"379","author":"JJ Baselga","year":"2012","journal-title":"The Lancet"},{"issue":"10","key":"ref13","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S1470-2045(14)70320-1","article-title":"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response","volume":"15","author":"EE de Azambuja","year":"2014","journal-title":"The lancet oncology"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13550-015-0103-5","article-title":"Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer","volume":"5","author":"AA Saleem","year":"2015","journal-title":"EJNMMI research"},{"issue":"7","key":"ref15","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ctrv.2009.06.007","article-title":"Trastuzumab versus lapatinib: the cardiac side of the story","volume":"35","author":"HH Azim","year":"2009","journal-title":"Cancer treatment reviews"},{"issue":"8","key":"ref16","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1185\/03007995.2013.807232","article-title":"Cardiotoxicity of novel HER2-targeted therapies","volume":"29","author":"MANMA Sendur","year":"2013","journal-title":"Current medical research and opinion"},{"issue":"23","key":"ref17","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1200\/JCO.2005.16.584","article-title":"Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas","volume":"23","author":"HA Burris","year":"2005","journal-title":"Journal of clinical oncology"},{"issue":"2","key":"ref18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10549-007-9860-9","article-title":"Pooled analysis of diarrhea events in patients with cancer treated with lapatinib","volume":"112","author":"JP Crown","year":"2008","journal-title":"Breast cancer research and treatment"},{"issue":"8","key":"ref19","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.4049\/jimmunol.159.8.3823","article-title":"Calcium ionophore-treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells","volume":"159","author":"BJ Czerniecki","year":"1997","journal-title":"J Immunol"},{"issue":"9","key":"ref20","first-page":"2531","article-title":"Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence","volume":"5","author":"MM Segovia-Mendoza","year":"2015","journal-title":"American journal of cancer research"},{"issue":"17","key":"ref21","doi-asserted-by":"crossref","first-page":"8132","DOI":"10.1073\/pnas.91.17.8132","article-title":"Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity","volume":"91","author":"PMP Guy","year":"1994","journal-title":"Proceedings of the National Academy of Sciences\u2014PNAS"},{"issue":"7","key":"ref22","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/emboj\/16.7.1647","article-title":"ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling","volume":"16","author":"DD Graus-Porta","year":"1997","journal-title":"The EMBO journal"},{"issue":"17","key":"ref23","doi-asserted-by":"crossref","first-page":"6871","DOI":"10.1158\/0008-5472.CAN-08-4490","article-title":"Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL","volume":"69","author":"LL Liu","year":"2009","journal-title":"Cancer research"},{"issue":"8","key":"ref24","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/onc.2013.41","article-title":"Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers","volume":"33","author":"DD Wetterskog","year":"2014","journal-title":"Oncogene"},{"issue":"10","key":"ref25","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.18632\/oncotarget.1148","article-title":"Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer","volume":"4","author":"AA Canonici","year":"2013","journal-title":"Oncotarget"},{"issue":"2","key":"ref26","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.immuni.2012.09.023","article-title":"Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor","volume":"38","author":"DM Zaiss","year":"2013","journal-title":"Immunity"},{"issue":"7437","key":"ref27","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nature11824","article-title":"T-helper-1-cell cytokines drive cancer into senescence","volume":"494","author":"HH Braum\u00fcller","year":"2013","journal-title":"Nature"},{"issue":"2","key":"ref28","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S1097-2765(03)00048-0","article-title":"The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors","volume":"11","author":"TPJTP Garrett","year":"2003","journal-title":"Molecular cell"},{"issue":"6","key":"ref29","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0092-8674(02)00940-6","article-title":"Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha","volume":"110","author":"TPJTP Garrett","year":"2002","journal-title":"Cell"},{"issue":"6","key":"ref30","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0092-8674(02)00963-7","article-title":"Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains","volume":"110","author":"HH Ogiso","year":"2002","journal-title":"Cell"},{"issue":"2","key":"ref31","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1097-2765(03)00047-9","article-title":"EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization","volume":"11","author":"KMKM Ferguson","year":"2003","journal-title":"Molecular cell"},{"issue":"6924","key":"ref32","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature01392","article-title":"Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab","volume":"421","author":"H-SHS Cho","year":"2003","journal-title":"Nature"},{"issue":"5585","key":"ref33","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1126\/science.1074611","article-title":"Structure of the extracellular region of HER3 reveals an interdomain tether","volume":"297","author":"H-SHS Cho","year":"2002","journal-title":"Science"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2010\/568938","article-title":"Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges","volume":"2010","author":"DRDR Siwak","year":"2010","journal-title":"Journal of oncology"},{"issue":"10","key":"ref35","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1128\/MCB.16.10.5276","article-title":"A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor\/neuregulin and epidermal growth factor","volume":"16","author":"EE Tzahar","year":"1996","journal-title":"Molecular and cellular biology"},{"issue":"1","key":"ref36","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0092-8674(94)90564-9","article-title":"A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling","volume":"78","author":"KLK Carraway","year":"1994","journal-title":"Cell"},{"issue":"1","key":"ref37","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1146\/annurev.cb.10.110194.001343","article-title":"Receptor protein-tyrosine kinases and their signal transduction pathways","volume":"10","author":"PP van der Geer","year":"1994","journal-title":"Annual review of cell biology"},{"issue":"1","key":"ref38","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0014-5793(97)00412-2","article-title":"The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions","volume":"410","author":"II Alroy","year":"1997","journal-title":"FEBS letters"},{"issue":"10","key":"ref39","doi-asserted-by":"crossref","first-page":"11310","DOI":"10.18632\/oncotarget.7023","article-title":"Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers","volume":"7","author":"SS Liu","year":"2016","journal-title":"Oncotarget"},{"issue":"40","key":"ref40","doi-asserted-by":"crossref","first-page":"21085","DOI":"10.1074\/jbc.M116.717892","article-title":"Amphiregulin Confers Regulatory T Cell Suppressive Function and Tumor Invasion via the EGFR\/GSK-3beta\/Foxp3 Axis","volume":"291","author":"S Wang","year":"2016","journal-title":"J Biol Chem"},{"issue":"10","key":"ref41","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ctrv.2015.08.001","article-title":"Mechanisms of lapatinib resistance in HER2-driven breast cancer","volume":"41","author":"VV D'Amato","year":"2015","journal-title":"Cancer treatment reviews"},{"issue":"1","key":"ref42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevOncog.v17.i1.20","article-title":"Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications","volume":"17","author":"BNBN Rexer","year":"2012","journal-title":"Critical reviews in oncogenesis"},{"issue":"6","key":"ref43","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.ejca.2012.11.019","article-title":"Resistance to BRAF-targeted therapy in melanoma","volume":"49","author":"RJ Sullivan","year":"2013","journal-title":"European journal of cancer"},{"issue":"17","key":"ref44","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1158\/1078-0432.CCR-14-2789","article-title":"EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors","volume":"21","author":"D. Ercan","year":"2015","journal-title":"Clinical cancer research"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0210209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T01:26:59Z","timestamp":1694568419000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0210209"}},"subtitle":[],"editor":[{"given":"Aamir","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,1,18]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0210209","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,18]]}}}